

United States Patent and Trademark Office
- Sales Receipt -

03/09/2006 MMAY22 00000001 500252 10712795
Sale Ref: 00000001 DA#: 500252 10712795
01 FC:1464 130.00 DA

Application No: 10/712,795

Attorney Docket No: DOC-0216US

I certify that this correspondence is being facsimile transmitted to the USPTO, or is being deposited with the U.S. postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re Application of: Crooke, et al.

Application No: 10/712,795

Filed: November 13, 2003

On 3/3/06


Pamela GrovesRECEIVED
CENTRAL FAX CENTER

MAR 03 2006

For: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

REQUEST TO CORRECT INVENTORSHIP

Pursuant to 37 C.F.R. §1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This paper is in reply to the Office Communication mailed on November 4, 2005, stating that the Petition to Correct Inventorship under 37 C.F.R. §1.48(a) filed May 20, 2005 does not comply with 37 C.F.R. §1.48(a)(3). Applicants submit herewith Petition to Correct Inventorship, pursuant to 37 C.F.R. §1.48(a), and in compliance with 37 C.F.R. §1.48(a)(3), to have Susan M. Freier added as a named inventor to the above-identified non-provisional application.

Susan M. Freier is a citizen of the United States of America, residing in San Diego, California, USA.

Applicants submit that the inventorship error occurred without deceptive intent on the part of the omitted inventor.

The inventors of U.S. Patent Application No. 10/712, 795 should be listed as follows:

Application No: 10/712,795

Attorney Docket No: DOC-0216US


Rosanne M. Crooke, Mark J. Graham, Kristina Lemonidis Tabet, Kenneth W. Dobie and Susan M. Freier.

Included herewith are: a Statement from the Assignee pursuant to 37 C.F.R. §1.48(a), a Statement under 37 C.F.R. 3.73(b), a Statement Confirming No Deceptive Intent on the part of the inventor, a Declaration pursuant to 37 C.F.R. §1.63, a copy of the Office Communication, and an Application Data Sheet.

Applicants believe that no fee is due with this paper as it is in response to the Office Communication mailed November 4, 2005. However, the Director is hereby authorized to charge fees due with the filing of this paper to the Isis Pharmaceuticals, Inc., Deposit Account 50-0252 referencing docket no. DOC-0216US.

Dated: March 3, 2006

Respectfully submitted,



Frances R. Putkey, Ph.D.

Registration No: 57,257
Isis Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008-7208